In the treatment of tumors using CTLA‐4 monoclonal antibody (ipilimumab), the patients showed significant upregulation of the Th1 and Th17 pathways and adverse reactions of inflammatory bowel disease.26, 27. This evidence concerns the gene CTLA4 and inflammatory bowel disease.